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METFORMIN 
 
ABSTRACT 
 
 
 
Introduction:  
Diabetes Mellitus is the most common endocrine disorder and Metformin 
is the most commonly prescribed oral hypoglycaemic agent. Metformin is well 
known to cause vitamin B12 deficiency due to effect on calcium-dependent 
membrane action in the terminal ileum leading to malabsorption of vitamin 
B12. The purpose of this study is to determine prevalence and associations of 
Vitamin B12 deficiency in patients of type 2 diabetes mellitus treated with 
Metformin. 
 Methods: This  cross sectional study  was carried out in department of  
diabetology, Combined  department of Biochemistry from 1st February 2015 to 
30  August 2015.We enrolled 45 outdoor patients of type 2 diabetes mellitus 
currently on Metformin for at least 12 months, by consecutive sampling, and 45 
age and sex matched patients on other drug were taken as control. Patients with 
vitamin B12 levels of less than150 pg/ml were said to be B12 deficient. The 
results were analysed on SPSS version 16. Results: Serum B12 levels were low 
in 17 patients (22%) on Metformin as compared to only 9 patients (8.6%) 
among controls,(p value 0.002). Mean B12 levels were significantly low in 
Metformin group  311 pg/ml (±194.4), p value 0.03. Dose of Metformin had 
inverse correlation with B12 levels and the difference was statistically 
significant with p value <0.001.  
Conclusion: Our study demonstrated significantly high prevalence of 
vitamin B12 deficiency in patients treated with Metformin. 
   Significant effect on dose and duration of Metformin use on B12 levels. 
Physicians must recognize this important fact and screen diabetics’ on 
Metformin therapy for underlying B12 deficiency. 
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INTRODUCTION 
 Diabetes mellitus is rapidly emerging as a current pandemic in this 
century.1 According to International Diabetic Federation 2014; nearly 183 
million people are still unaware that they are living with diabetes. 
Therefore the identification of individuals at high risk of getting diabetes 
is of great importance for investigators and health care providers.2 The 
target is to reduce the prevalence of the disease and its economic burden 
and enhance quality of life for all persons who have and are at threat of 
Diabetes Mellitus.  
 It has equal priority in both developed and developing countries. It 
is attracting the world since the global crisis due to diabetes cripples not 
only the health but also the economy of every country. The glad news is 
that once the risk factors are accessed the development of Type 2 
Diabetes can either be deferred or even prevented by healthy customs. 
 The Greek Apollonius of Memphi first used the term "diabetes" or 
"to pass through" in 230 Bc1. (2) The Indian physicians, Sushruta and 
Charaka were the first to identify Type 1 and Type 2 Diabetes as two 
separate conditions. In the late 17th century Britain John Rolle added the2 
term "mellitus" or "from honey" to separate the condition Diabetes 
insipidus.  
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Diabetes - a multisystem disease due to defect in metabolism of 
glucose which causes multiple irregularities in the metabolism. 
Metabolism of glucose is well organized by multiple hormones and 
neurotransmitters in response to nutritional3, emotional and 
environmental changes. Unger, first labelled diabetes, as a “bi-hormonal” 
disease.3  
 Conventionally the pathophysiology of T2DM was engrossed on 
beta cell dysfunction and insulin resistance in liver and skeletal muscle. 
Numerous researches in the past two decades exposed a basic 
understanding about mechanism and dysfunctions in gastrointestinal tract, 
pancreatic alpha cells, adipose tissue, brain and kidney that produced a 
more tough picture of Type 2DM4 
 
 Many studies in pathology of the disease had introduced the novel 
drugs alike pancreatic-protein-coupled fatty-acid-receptor agonists 
inhibitors of the insulin-releasing glucokinase activators, 11ß-
hydroxysteroid dehydrogenase, sodium-glucose cotransporter 1, glucagon 
like peptide-1 analogues, glucagon-receptor antagonists and quick-release 
bromocriptine, dipeptidyl peptidase-IV inhibitors, and metabolic 
inhibitors of glucose output from liver 5  
 Diabetes is a multifaceted process and includes managing disease 
complications, drug related adverse effects in addition to glycemic 
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control. There are supporting evidences that various parallel interventions 
improved clinical outcome in these patients. Though so many novel drugs 
are available, the incidence of Type 2 DM is still in the advanced end.6  
 
 The American Diabetes Association advises biguanides like metformin 
must be the primary therapy forT2DM .When used alone it rarely causes 
hypoglycaemia. It increases sensitivity to insulin and increases weight 
loss and alters lipid profile7reasonably. Metformin acts through 53 
enhancement of activated protein kinase of adenosine monophosphate 
(AMPK) system to decrease sugar levels in the blood. The main activity 
of the drug is on gluconeogenesis9.in the liver  
 
Adverse events of the therapy are intestinal disturbances and, 
seldom disturbances in the muscle gluconeogenesis called lactic acidosis 
in addition to vitamin B12 deficiency which is commonly overlooked and 
the monitoring is for clinical side-effect1011, Pflipsen et al. i indicated that 
22% of cases had a B12insufficiency in 2009, and person who are 
prescribed the above drug had reduced vitamin B12 levels.  
While Lactic acidosis manifests only in the setting of heart failure, 
renal failure and alcoholism, it is uncertain whether vitamin B12 
malabsorption is due to DM itself or to biguanides 8  
Ting et al. publicized that if the drug advised for chronic period it 
causes decreased B12 levels. It is dependent on the amount of the drug. 
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The mode action of the drug is unknown. It is mainly by changing the 
movement of the intestine or intracellular handling of calcium, thereby 
reducing absorption of vit.B12. It is accepted that calcium restores the 
deficiency10. 
 It is significant to identify the impact of B12 insufficiency. B12 is 
necessary for, cellular repair DNA synthesis and for the regular synthesis 
of RBC 912  
 13 B12 is necessary for the metabolism of dopamine, monoamines 
and serotonin. Because of vitamin B12 deficiency, all of the above neuro 
transmitters’ synthesis will be deficient which collectively end in 
neurocognitive or psychiatric manifestations, Axonal degeneration 
demyelination and neuronal death. Vitamin B12 deficiency induced 
neuronal damage manifests as autonomic neuropathy and peripheral 
neuropathy sub- acute combined degenerate ion of the spinal cord,13 14  
 Chronic metformin use results in reduced level of VitB12 which can 
exacerbate or cause peripheral neuropathy due to DM. Because of the 
action of the glycation end products on vascular endothelium diabetics 
are more vulnerable for diabetic neuropathy. Unluckily the manifestations 
of diabetic neuropathy overlap with the paraesthesia impaired vibration 
sense, and impaired proprioception related with Vitamin 
B12deficiency.1314 
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As a consequence, B12 deficiency–induced neuropathy may be 
confused with diabetic peripheral neuropathy. Recognizing the exact 
cause of neuropathy is crucial, because simple vitaminB12 
supplementation may revert neurologic symptoms improperly attributed 
to hyperglycaemia 
 6
AIMS AND OBJECTIVES 
Metformin and life style modifications are the first line therapy in 
type 2 patients as per the ADA. It is well tolerated by most of the type 
2DM persons. But the main adverse effect is vitamin B12deficiency 
which is almost forgotten and the viaminB12screening is rarely advised  
Primary aims of the research are to identify “the prevalence of 
vitaminb12 deficiency in T2DM persons on metformin”, and compare 
them with those patients receiving other hypoglycaemic agents. The 
secondary objective is to advise base line screening of vitamin B12 
before starting the drug.    
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REVIEW OF LITERATURE 
 
In the 21st century next to China, India leads the world with the 
most number of Diabetics aptly termed as Diabetic capital of the world. 
In 2000 31.7 million people suffered from Diabetes but in 2015 it is >62 
million. China has an incidence of 20.8 million, in USA it is17.7 million, 
where as in INDIA it is7118 million. The global incidence of DM is 366 
million and the chief contributor is India. 
By 2030 the incidence of type2 DM in India will be 79 million and 
for china it is42.3million and for US it will be30.3million. Rendering to 
new valuations, approximately 285 million individuals worldwide (6.6%) 
in the 20–79 year age crowd will show diabetes in 2010 and by 2030, 438 
million people (7.8%) of the mature people will have the disease. 
In India, the persons in rural and urban areas were equally affected 
by diabetes; Urban India has a higher incidence of 5.6% than Rural India 
with 2.7. The high prevalence observed in urban area shows that the rapid 
urbanization plays a major role. The most worrying trend in incidence of 
diabetes is its shift towards younger age where Diabetes commences ten 
years earlier than in western countries20. In Chennai, diabetic prevalence 
was 13.5% in 2000 that went up to 14.3% in 2004 and reached 18.6% in 
200620. 
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The increased prevalence of type 2 DM in urban regions is due to 
the fact that people are having easy access to diagnosing diabetes. In rural 
regions food insecurity, dominance of communicable diseases, illiteracy, 
lack of counselling, poor sanitation, inadequate infra-structure in 
screening, and long travel to reach health care facilities (20) are the reasons 
for the decreased prevalence. 
Quite a lot of studies on migrating Indians across the world have 
revealed that Indians having a greater risk of developing T2 DM and 
metabolic irregularities matched with other racial groups. Though the 
primary cause for these problems is still vague, some unique biological 
variables of this race called as the “Indian phenotype”- was thought to be 
one of the main causes accounting to the increased tendency towards type 
2 diabetes, in spite of low incidence of obesity.  
Increased abdominal obesity in Indians is due to more waists to hip 
ratios and waist circumference. Again, in Indians for any given BMI there 
is greater total abdominal, visceral body fat. So increase in the incidence 
of insulin resistance occurs. They also have reduced levels of the 
protective adiponectin and adipokine and have raised metabolites of 
adipose tissue. Studies on newborn indicate that Indian babies are small at 
birth but fatter when compared to babies of other races and are mentioned 
as “the lean fat Indian babies”. 
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A recent study concluded this finding and has found that the “lean 
fat phenotype” in newborns was present throughout the life of the Indian 
child and this would lead to the diabetogenic adult. These results propose 
that Indians are vulnerable and predisposed to become diabetics with 
associated metabolic complications. 
Genetic variables that control fat distribution and metabolism of 
glucose need to be explained for the better understanding of the 
pathogens is of diabetes. These studies have concluded that certain genes 
are responsible for the increased prevalence of diabetes in Indians. Few 
genes that are protective for the Europeans do not have the same action in 
the Indians. 
 The epidemiological transition of Type II DM   
The intense rise in the incidence of type 2diabetes and the 
connected disease associated with it for example, obesity, hypertension 
and the syndrome x might be linked to the fast life style habits during the 
last 50 yrs. Though this” epidemiological transition”22, which comprises 
better-quality nutrition, improved hygiene, control of several infectious 
diseases and better-quality access to quality health care have ended in 
prolonged expectancy, which causes the current diseases like obesity, 
diabetes and cardiac diseases. Western life style introduction into these 
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societies led the shocking trends in obesity and the linked metabolic 
complications. 
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According to NEEL THRIFITY hypothesis the specific genes 
designated in the former millennia (Indians) permitted survival during the 
starvation by powerfully glowering all energy obtainable during times of 
festival. This genetic factor leads to type 2DM and obesity when bare to 
continuous high energy diet. 20 
The modern trend, adolescent’s children and young adults are the 
victims for Type 2 diabetes and pre diabetes in countries like Japan, USA, 
India, Australia and UK. According to Bloomgarden et al., the earlier the 
age the greater is the burden, as the major complications fall on the future 
generations. 
Diabetes is meant by a group of metabolic defects of variable 
etiology which is branded by overt hyperglycaemia and other 
abnormalities of glucose metabolism due to deficiency of insulin, insulin 
secretion or both. Major forms of diabetes are; type 1 and type 2. 
Deficiency of or severe reduction in insulin secretion due to 
immunological or viral destructions of ß cells is the reasons for type  
1 diabetes, which credits for 5-10% of diabetic populations. The more 
predominant form, DM 2, accounts for more than90% of cases (Olefsky, 
2001).20  
 
 12
Diabetes type 2 typically20 starts as resistance, to insulin.  
In this disorder the insulin is not properly used by the cells. As the insulin 
need is increased, the pancreas loses its ability progressively. Deficit of 
insulin action and/or secretion brings hepatic glucose output by inhibiting 
glycogen synthesis and stimulating glycogenolysis and gluconeogenesis. 
This particularly results in fasting hyperglycaemia (Defronzo an 
Simonson, 1992 and Michael et al, 2000)20  
CLASSIFICATION  
WHO (1999) published a revised classification which is mostly 
followed. This covers both clinical and etiological types of diabetes 
mellitus. 
Diabetes Mellitus - Etiologically classified into four categories  
I. Type 1 Diabetes (typically show absolute insulin deficiency since the 
β cells are destroyed).  
 A. Idiopathic 
 B. Immune mediated. 
 II. Type 2 Diabetes 
 This is due to insulin resistance along with virtual insulin β cells 
deficiency or by defects in the secretion mechanism. 
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III. Other Types 
A. Genetic defects in insulin action 
B.  Diseases of the exocrine pancreas 
C Genetic and Epigenetic defects of β- cells 
D. Drug or chemical induced 
E. Endocrinopathies 
F. Uncommon forms of immune-mediated diabetes 
G. Infections 
H. Other genetic syndromes sometimes associated with diabetes  
IV. Gestational diabetes mellitus.  
 Clinical staging of T2DM 
1. Normoglycemia  
2. Impaired Glucose Regulation- and Impaired Glucose Tolerance 
(IGT)  
3. Diabetes mellitus  
4. Impaired fasting Glycaemia(IFG) 
The majority of cases drop into first two classes of diabetes 
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Pathophysiology behind Diabetes: 
Diabetes is a condition where, chronic elevation of blood sugars is 
seen. The chief defect is in the metabolic pathway of carbohydrate. 
Carbohydrates are not only the main energy yielders they also needed for 
exact cellular purposes and protein alterations by glycosylation. 
Therefore the body has to sustain the blood glucose levels within narrow 
limits which are maintained by many hormones of which, the important 
action is through Insulin.  
Insulin is the chief hormone of blood glucose regulation.. Insulin 
rises glucose level by promoting gluconeogenesis in peripheral tissues, 
also promotes lipogenesis, cell growth and differentiation. It also 
enhances protein synthesis glycogen synthesis, glycogenolysis, lipolysis 
and protein interruption in liver and muscle. So continuous deregulation 
in the action or secretion of these processes and causes the changes in the 
fasting lipid and fasting glucose levels. 
RECPTORSFOR INSULIN SIGNALLING 
Insulin action starts by attachment of the hormone to exact insulin 
surface receptors. Insulin receptor Coding Gene is INSR.19 This receptor 
possess bi functional glycoprotein subunit domains: an extracellular 
alpha-subunit covering at most hormone binding site and beta subunit 
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with intrinsic tyrosine kinase activity.20 Insulin provokes a wide-ranging 
biological replies by attaching to its exact receptor. Attachment of insulin 
to the alpha subunit creates a conformational change which ends in the 
auto phosphorylation of a sum of tyrosine residues existing in the beta 
subunit 21.30 Insulin receptors trans phosphorylate several subsequent 
substrates including –and Gab 4, IRS1 1, Cbl, and P60dok APS, 31. After 
phosphorylate ting to tyrosine kinase, the above mentioned molecules 
connect with over their SH2 domains, produces a mixed series of 
signalling ways of the concerned hormones.  
i. Ras and MAP kinase cascade 
ii. Activation of PI(3)K/Akt pathways 
iii.  Cbl/CAP These pathways performances in a harmonized way to 
control glucose, lipid and protein metabolism 
Akt pathways & PI3 kinase 
PI3 kinase plays a main role in the regulation and in the expression 
of insulin hormone. The heterodimer PI3 includes of the p85 regulatory 
subunit and p110 catalytic subunit. Activated PI3K go and activates, 
PIP2, PI3P and PIP3respctively. The phospholipids proteins are reported 
as the second line conveyers of message. This protein operates with a 
help of threonine kinases and serine3, 4, 5 kinases. These proteins transport 
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Akt to the membranes from cytsol via attaching with "pleckstrin 
homology domain kinases.3. Transport of the lipids and the attachment of 
receptors create differences in charge. With the help of PDK1, Akt 
activities are stimulated by means of phosphorylation.  
If Akt phosphorylation is initiated it controls the many regulator 
proteins which are followed in the succeeding path ways of cellular 
function of carbohydrate metabolism. Amongst others, Akt 
phosphorylates and panels components of the, protein kinase C (PKC) 
isoforms GSK3and glucose transporter 4 (GLUT4) complex all of are 
`vital for assisting the biological activities of the hormone of insulin34,35 
 Insulin- MAP kinase pathway  
Insulin excites the of mitogen kinases protein present in this path 
which are already stimulated. Because the mitogen kinas are activated it 
results in the phosphorylation of IRS and tyrosine kinases proteins .Next 
it stimulates the connector Grb2 to, recruiting the Son-of-seven less 
(SOS) interchanger enzyme to the membrane. which in turn go and 
activates the Ras.37 After the activation of the tyrosine phosphatases then 
SHP2 lastly the Ras are stimulated. Since the activated Ras are connected 
with receptors like IRS1/2or Gab-1. As soon as stimulated, Ras works as 
a biological switch, exciting a chute of serine kinase like chain of action 
follows MEK Raf, and ERK. Activated ERK will trans -lodged to the 
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nucleus, where it causes of transcription and phosphorylation of essentials 
such as TCF, p62 prompting a cellular proliferation or differentiation31, 
Insulin resistance & Type 2 diabetes mellitus 
It is demarcated as a defective response in target tissues such as the 
skeletal muscle, liver, and adipocytes, to act of normal level of insulin. 
Current situations insulin resistance plays major role in the 
developmental stages of T2DM. Mainly to overcome this situation 
endocrine system produces the concerned hormone which allows the 
person for better withstanding of regular glucose Level.40 During the 
period of time, progressive loss of cells and incapability of pancreas 
causes a condition absolute insulin insufficiency and later the stage of 
T2DM.. This resistance to insulin is the chief issue leading to the 
pathophysiology - T2 DM41.  
MECHANISM BEHINDTHE DISEASE 
Several mechanisms has been showed as reason for insulin resistance,  
1) Insulin sustains blood sugar within a very critical range.  
Raised glucose load, glycaemic fluctuations and the pancreas is 
enforced to over-secrete insulin. Continuing hyperglycaemia roots to 
failure of the beta cells of endocrine pancreas to secrete insulin and later 
may cause Type 2 Diabetes Mellitus. Eventual analysis shows that 
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normal glucose tolerant person with a elevation of pancreatic glucose 
burden have an better risk of emerging Type 2 diabetes compared to 
person with a low pancreatic glucose level. Mechanisms consist of 
reduction in expression of related genes (GLUT2insulin receptor, rectifier 
potassium channel, glucokinase,) beta cell differentiation in addition to 
greater risk of apoptosis.41  
2. Lipid Accumulation liver & adipose tissues 
Increased lipid levels in skeletal muscle and, augmented liver 
triglycerides are the root cause of insulin resistance. Increased insulin 
level in the blood is complicating the lipid synthesis in liver and muscle is 
promoted through SREBP1c - regulatory element-binding protein 1c 
representation at the genetic level.43 The chief regulator in de novo lipid 
synthesis at genome level is SREBP1c - l. Liver, adipose tissue and 
skeletal muscle, since the lipoprotein lipase is over stimulated, lipids 
getting accumulated and leads to resistance. Plentiful studies point out 
that chronic exposure of the pancreas to elevated FFA levels has harmful 
effect on the beta cells44.  
Insulin Resistance by FFA 
In skeletal muscle, accumulation of lipid will ends in raised ratio of 
NAD /NADH+ acetyl CoA/CoA –in the mitochondrial level. This ends in 
the PDH (pyruvate dehydrogenase) inhibition. These causes , elevation in 
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the citrate level in the carbohydrate metabolism. This in turn causes 
phosphorylation of phosphofructo kinase so the glucose-6-phosphate 
levels are raised at the cellular level. This will deactivate the enzyme 
hexokinase II ending in raised glucose levels in the cells and reduced 
glucose utilisation in the muscle. 
46Another explanation is given for the lipid accumulation and 
subsequent development of resistance in muscle is accumulation of 
metabolites of lipids in the cells such as, fatty acyl CoA, ceramides and 
diacylglycerol. This lipid and lipid metabolites accumulation within 
skeletal muscle and liver activate serine kinases cascade through PKC-ε, 
reduced insulin signalling at receptor level. Decreased, tyrosine and IRS-
2– activity ends in phosphorylation of PI 3- kinase,  
47 Defective IRS-2 either in molecular or in the site of action level 
reduces the activity of glycogen synthase, this in turn causes decreased 
glucose absorption and decreased liver gluconeogenesis. The above 
mentioned reaction is insulin dependent defective PI-3 mediates defective 
activity of GLUT-4 in the membrane. 
Low AKT2 activity 
49Lowered activity of AKT2 results in dec reased phosphorylation 
of fork head box protein O (FOXO), letting it to enter the nucleus and 
trigger the transcription of the rate-controlling enzymes of 
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gluconeogenesis (carboxykinase, glucose-6-phosphate phospho-
enolpyruvate phos-phatase). Amplified gluconeogenesis further worsens 
hepatic insulin resistance and results in fasting hyperglycaemia 50 
D. PHARMACOLOGICAL AND OVERALL APPROACHES TO 
TREATMENT OF DM (ADA-2013) 
 1. Remedy for type 1 diabetes 
 Guide lines 
1.  Maximum individuals of type I diabetes are managed by multi dose 
insulin injections -three to four injections of basal and prandial 
insulin or constant insulin infusion of subcutaneous type -CSII 
2.  Al most all type 1 diabetics are explained about the increase or 
decrease of insulin dose according to fasting and post prandial 
blood glucose level and also the expected outcome.  
3.  Many of the diabetic of type 1 diabetics are advised to use 
analogues of insulin to decrease hypoglycaemia complications.50 
4.  Immunological screening is advised to do in the expected cases.51 
5. Short- and intermediate-acting insulin is recommended in the 
initial stages irrespective of micro vascular complications. 
Exhaustive insulin treatment was associated with unexpected 
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hypoglycaemia .Out of hundred, sixty two cases will have severe 
hypoglycaemia. Meanwhile many long acting and rapid acting 
preparations are available. These are having less adverse events. 
Treatment is individual based and also dependent on the micro 
vascular status of the individual. Strict glycaemic status is 
followed. 
6. Insulin analogues are used in cases of or recurrent hypoglycaemia. 
Many guide lines are available regarding tight glycaemic practise. 
Since many of the type 1 DM are due to auto antibodies.  
So screening for thyroid antibodies, pernicious anaemia, coeliac 
antibodies are advised.51 
7.  Therapy for hyperglycaemia in type 2 diabetes  
Metformin is first drug of choice forT2DM. In the absence of 
contraindications, if well tolerated it is the primary drug of choice. 
1.  Newly diagnosed T2 DM having definite signs and high levels of 
A1C, insulin is recommended either as single drug or with other 
OHAS. 
2.   If severe hyperglycaemia persists after six months of single drug 
therapy, another drug like GLP-1 included. 
Reduction of basal liver gluconeogenesis within the physiological 
limit is the expected outcome of the diguanides. This activity is combined 
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with the inhibitory role in the electron transport chain is, later proved in 
the literatures. The lactic acidosis which is the most serious adverse event 
of the drug is mainly due to the mitochondrial inhibition rather than 
therapeutic effects.55  
  Metformin has minimal influence on ATP levels of the cells, even 
when using in more concentration. The sugar reducing activity is chiefly 
due to the inhibitory effect on the complex I of the electron transport 
chain. This is individualised for every diguanides which are already 
exists. 
  The effect on mitochondrial ETC, the decreased oxygen 
consumption and Combining the TCA cycle for ATP which fulfils the 
energy needed for the every activity of each cells in the body.  
  This is proved in a study which was conducted in the year 2000. 
Studies on, freeze-clamped livers hepatocytes showed that metformin 
reduces the basal liver glucose output by inhibiting complex I in the 
mitochondrial electron chain. 
  The biguanides blocks the oxidation of glutamate and malate in the 
citric acid cycle more effectively. This proved that the target place for 
metformin is the complex I of ETC. Succinate a substrate which acts as a 
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complex II can bypass complex I action of metformin. Similar researches 
completed before by other guanide-containing drugs also66.  
This study gives evidence of association between reduction in 
glucose output and inhibition of complex I in electron transport. But it is 
not genetically proved. So to prove the site action of metformin more 
researches are needed 
Complex I inhibition also gives a correct explanation of lactic 
acidosis in metformin treatment. Lactate levels increased by glycolysis 
should be expected to complex I inhibition comparing with buformin and 
phenformin, lactic acidosis is less common with metformin. This 
metformin-dependent mitochondrial inhibition is assumed to be self-
limiting as the mitochondria is active.68  
The Mechanism of Activity 
The mechanism defined for the drug action is reduction in the basal 
hepatic output of glucose. The T2DM patients have much more 
gluconeogenesis than normal. Metformin reduces this to one-third. It 
activates the first component of ETC in the mitochondria since the 
protein kinases stimulate the cyclic AMP. This is done with help of 
glucagon. Because of the activated protein kinase the mitochondrial 
glycerophosphate dehydrogenase activity is reduced .69  
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AMPK, is having important activity in the various metabolisms 
like protein and fats and its chief activity is concerning with the insulin 
hormone signalling. It is needed for metformin's inhibitory action on 
complex I. Stimulation of AMPK is essential for the improved 
representation of the small heterodimer, which go and suppress the 
representation of the important enzymes like glucose 6 phosphatse, 
corboxy kinase, and phosphoenal pyruvate kinase at the genetic level. 
The biguanides action on AMPK remains unknown.  
70Raised cellular level of AMP also been proposed for the raised 
cAMP by glucagon and, also the activated kinase of protein system 
activity is antagonized by metformin. Thus reduces the fasting 
hyperglycaemia. Metformin also brings a strong alteration in the faecal 
micro flora in diabetic mice, and it may be a consequence of GLP 1like 
activity. 
71Metformin not only controls hepatic gluconeogenesis, also 
increases sensitivity to insulin. It stimulates the activity of GLUT -4 in 
the peripheral tissues by phosphorylation. It also causes reduced fatty 
acid oxidation which is mediated by insulin and also reduces the uptake 
of glucose from the intestines. By enhancing the activity of insulin to its 
receptor it stimulates more utilisation of glucose in the peripheral tissues. 
This is also proved in type 1DM also  
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Activated kinases are having primary role in the function of the 
biguanides. Activated kinases, promotes dislocation of GLUT receptors 
in the intestinal membrane which reduces the glucose uptake in the 
absorption levels itself. Some activities of the drug are without the 
involvement of phosphate kinases. This is proved in heart muscle.71 
Pharmacokinetics 
In fasting Conditions the oral bioavailability is 60%.The absorption 
is slow. Three hours after the intake, maximum concentration of plasma 
is achieved in the regular formulas. Seven to eight hours in the sustained 
release.72 
In the body PH it is having the pKa of 2.8 -11.5. The p Ka makes 
the drug a harder base. It is less soluble in lipids. It is diffuses passively 
in the membranes of plasma. The double methyl substituent of metformin 
offers minor lipid solubility than phenyl ethyl side chain in its other drug 
phenformin. The lipophilic character of metformin is used for producing 
prodrugs with better oral bioavailability than metformin59. 
Tubular excretion is the mode of clearance from the body. In the 
urine it is eliminated without any changes. After 24 hours of intake it is 
not detected in the plasma. Normally it is eliminated from the plasma 
within 6.2 hours. 
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Contraindications 
The drug is contraindicated in chronic kidney disease persons. (If 
CR is more than 1.7) It is contraindicated in chronic liver disorders, 
progressive parenchymal diseases of the lung and also in congestive 
cardiac failure. Since cardiac failure persons may develop the fatal 
condition called lactic acidosis. 
Metformin is temporarily withdrawn before any radiographic 
study including iodinated contrast agents, such as a contrast-enhanced CT 
scan or angiogram, as the contrast dye may induces short term 
impairment in kidney function, ultimately leading to lactic acidosis by 
initiating retention of metformin in the body. Metformin is restarted two 
days after the investigations.61  
Adverse effects 
1. The most common effect is gastrointestinal upset like diarrhoea, 
cramps, nausea, vomiting, and increased flatulence. 
2.  The most severe and rare side effect is lactic acidosis. The vast 
majority of these cases are related to other complication such as 
liver or kidney dysfunction, rather than to the drug itself. 
3. Metformin reduces the levels of thyroid-stimulating hormone in 
hypothyroidism persons. 
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Gastrointestinal 
1. Gastrointestinal upset can cause severe discomfort after the first dose. 
If the drug is started with a minimal tolerable dose this adverse event 
is overcome. The dose should be adjusted progressively 
 The most severe adverse event of duiguanides is lactic acidosis 
-MALA- metformin-associated lactic acidosis.  
 Prevalence MALA is 9/ 100,000 human-years.  
  The lactic acidosis – that is lactate taken to the hepatic tissue is 
reduced while using metformin, since the source for 
gluconeogenesis is lactate, a route in which the drug survives. 
But this is seen more in phenformin.  
Interactions 
The H2-receptor blocker cimetidine raises the plasma levels of 
metformin. The two drugs were eliminated from the kidney by the 
mechanism called - (tubular secretion). Predominantly the clearance of 
cations.Both the drug competes through same transportation 62 
 One case control study revealed cephalexin an antimicrobial drug 
also increases the duiguanides levels by the same way. 
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OTHER THERAPEUTIC USES 
1. Pre diabetes 
2.  Polycystic ovary syndrome 
3.  Gestational diabetes 
4. Anti cancer activity 
Pregnancy 
In GDM (gestational diabetes) and also in pregnant diabetics the 
safest drug is metformin. When the drug is prescribed, the mothers had 
less weight gain comparing with mothers on insulin. Neonates of mother 
who received metformin had minimal visceral adiposity .Since the future 
obesity related disorders are reduced in these children. 
Researches 
  Duiguanides specifically used in modules of ovarian, pancreatic, 
lung, a prostate breast, colon cancer cells. To test its efficacy in antitumor 
tissues studies are going on. The first clinical trials confirmed an 
advantageous effect in breast and colon cancer .Inhibiting action of the 
drug over the first component of respiratory chain increases the potency 
of radiotherapy by reducing free radicle formation. 
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Although it is used in various diseases the use of the drug in type 2 
DM is unbeatable so far. Sustained use for long duration causes elevated 
homocysteine level in blood and also raised rate of vitamin 
B12 deficiency, so the investigators are advised to screen for the 
vitaminB12 deficiency annually.  
THE EVOVLUTION OF B12  
64 Pernicious anemia when it was discovered, a fatal condition, B12 
was the cure which was revealed accidently. The researches in anemia 
were conducted by the great man called GEORGE WHIPPLE, he used to 
give different types of foods to dogs after bleeding them to see which 
type of food allow them fast relief from the anemia produced 
He noticed that liver in large amounts cured the anemia caused by 
bleeding. Finally he came to know the truth liver extract corrected the 
B12 deficiency anemia. 
Later on after several studies George Richards Minot and William 
Murphy found a separate compound of hepatic origin corrected the 
vitamin deficiency in dogs, and they thought it may be iron. Later the 
team came to know the truth the compound corrected the bleeding 
disorder in dogs and human are entirely different one. The liver extract 
which cured pernicious anemia was discovered like this. Minot and 
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Murphy explained this in the year 1926. This is the evaluation of 
vitaminB1265.  
Edwin Cohn a famous chemist (in1928) prepared a hepatic juice 
like compound with 100times the potency of normal liver. The primary 
medicine for pernicious anemia was found in this way. For their 
principle, in pernicious anemia Whipple, Murphy and Minot, were 
awarded with Nobel in the year1934 for their great work in the field of 
physiology.  
Discovery of the vitamin B12 came to an end like this. B12 is 
mainly isolated from bacterial broth. It is a chief water soluble vitamin. In 
the year 1947, in University of Maryland, Mary Shaw Shorb, were 
employed for the Poultry Science in a combined assignment with Folkers 
and Merck. They were given $400 dollar award for the "LLD assay" of 
B1266.  
Lactobacilli lactis Darner is called as LLD. A bacterial group 
needed for the “LLD” preparation which contains the growth promoting 
substances. Finally the growth promoting substance was named as 
vitamin. B12. Shorb and his assistants utilized the LLD for fast extraction 
of the anti-pernicious anemia factor from liver extracts. Folkers of the 
United States and Alexander R. Todd of Great Britain67, with the support 
of the chemists Shorb, Karl A,isolated the B12 in the pure form in the 
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year1948, for which they were respected by the American Society of 
Nutritional Sciences with Mead Johnson award.  
 The chemical configuration of VitaminB12 was constructed by 
Hodgkin and Dorothy Crowfoot in1956. It was possible with help of x 
ray crystallography. The good manufacturing ways were came to market 
in 1950.68  
  With the sincere work of hundred scientists over eleven years, 
Woodward and Eschenmoser elucidated the vitamin B12. 1972 they also 
explained the procedure for isolating the vitamin from liver extract. 
During the isolation process of vitamin B12, an artefact was found out 
and it was named as cyanocobalamin. Red methylcobalamin- MeCbl 5’-
deoxy-5’-adenosylcobalamin-Adocbl which is yellow coloured are 
biochemically significant forms of co factors of vitamin B12. 
The B12 carrier -proteins studies through X ray crystallography 
have identified the use of Cbl-based bio conjugates in the imaging 
techniques. Because of these works Cbl-based bio conjugates are used as 
vehicles for targeted drug delivery in cancer tissues. It has created a new 
therapeutic era of vitamin B12. 
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Structure 
70chemical structures are having a complicated process .The base is 
corrin ring which has the similarity of HB of porphyrin, cytochrome, 
chlorophyll. It is centred on a metal cobalt ion. Among the six 
coordinating places the four are given by the corrin ring. 
Dimethylbenzimidazole assembly contributes the fifth place. The last 
place, which is the centre for reaction, which is adjustable, so that 
hydroxyl (-OH), a cyano (-CN), a methyl groups (-CH3) or a Ado cbl'-
here the fifth carbon in the deoxyribose sugar get attaches covalently with 
Co. consistently, the four B12 arrangements are made in this way’ the first 
bond explained in biology is C-CO which was explained during the 
elucidation of B12 structure only. Enzymes hydrogenases related with 
cobalt use, includes metal-carbon bonds. 
Vitamin B12 is a collective description given to represent the group 
of corrin ring and cobalt. The hydrogenases are required by 
these elements for their accurate vitamin role in the body. All the 
compounds having, cobalt-corrin fragments, has to be synthesized by the 
bacteria.  
  By way of enzymatic exclusion of certain prosthetic organic groups 
from the cobalt atom, the human can transform any form of B12 to its 
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active form. Due to the nature of cobalt ring, all the vitamer forms are in 
deep red colour only. 
Cyanocobalamin is “vitamer"71, form of B12. Actively metabolised 
to its co enzyme form in the body. On the other hand, the 
cyanocobalamin is not classically present in nature. The methyl and 
adenosyl forms creates strong attachment with cyanide (-CN). The 
cyanocobalamin of B12 is crystallized easily. It does not undergo air-
oxidation. Cbl is used as food additive in all the commercially available 
multivitamin preparations. Pure form Cbl are seen in dark pink colour is 
due to extreme octahedral cobalt(II) compounds and the minerals can be 
simply powdered to millimetre size. 
The Co atom of the Cbl is correctly coordinated with seven amide 
side chains and by corrin ring (a-g). The numerical and assembly of the 
atoms and the complicated molecular arrangements were revealed by 
Hodgkin Dorothy . 
The corrin ring includes four oxidized pyrrole rings, A-D, having a 
straight link among A and D, rings having helical solitary complete R-
arrangements in its spiral midpoints between C19- C1. The side chain is 
connected through an amide bond with nucleotide with the support of 
benzeimidazole 5-6 which harmonizes Co at the axial spot on the side of 
corrin. Cobalamines+3are (octahedral) are due to oxidized state of cobalt 
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base-on form synchronised with the axial X ligand with the left arm of 
corrin ring. On protonating the NB3 atom with benzimidazole relations 
Cobalamins can be proceeds the base-off form changed through 
endogenous ligand. 
Oxidized form of co (II) is presented without a axial ligand and 
commonly recognized as cobalamin II or B12, but in co (I) form it is seen 
as the tetra coordinated base off form. Coronoids will have the structural 
modification depending on the cobalaminss,  
CNCbl, does not have direct organic functions while MeCbl and 
AdoCbl(X=5’deoxyadenosylcobalamins) act as prosthetic, group for 
many enzymatic reactions. The cofactor role is due to the metal bond of 
corbon enzymatic catalytic replies are depends on the breaking and aking 
(Cobalamins) of the Co-C bond.  
MeCbl is the coenzyme of numerous methyl transferases, such as 
methionine synthase, meant for the synthesis of methionine in bacteria 
and humans. Methyl corrinoids, are the coenzyme in the carbon dioxide 
fixing path ways in the aerogenic methanogenic bacteria  
The cofactor every time fixes the Apo enzyme in the base-off form 
and, in a subgroup of methyl transferases, the Co is co-ordinated through 
a histidine scaffold in the /His-on binding protein 8 of base.1 
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75 For eliminases and isomerases,AdoCbl is the cofactor- which 
moves one -2 a H atom from a electronegative cluster to the proceeding 
carbon like L-methylmalonyl-CoA-mutase-.MMCM Catalyses revocable 
conversion of to the succinyl COA L methylmalonyl COA remainder in 
bacteria and mammals. 
The only adenoxyl cobalamine containing enzyme in the body is 
methylmalonyl COA mutase. In the nucleotides Ribonucleotide reductase 
class II MMCM is the cofactor. Co-Ado bond cleavage is done only 
through the adenoxy cofactor sulphidogenic microbes (are used to de 
chlorinate aliphatic and aromatic chloro-hydrocarbons) uses coblamines 
as coenzymes. 
B12 group of coenzymes consists of Fe4S4 and Fe3S clusters 
along with corrinoid. The corrinoid, is a novel cofactor for tetra chloral 
ethylene. The quite interesting story of the 2 cofactors MeCbl and 
AdoCbl is the Co-C bond, is widely taken into account as its cleavage is 
interesting role in the pathways of many metabolism.75 
B12 Dependent Enzymes 
Methyl transferase  
76Corrinoid methyl transferases designs have been explained. It is 
explained through 3 models by Mathew’s rowina. 
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78The principal form, Co (I) of the corrinoid résumés a methyl 
group from the substrate methyl-donor (D-CH) n the external module and 
Co(III)-CH transfers its methyl to the methyl-acceptor (A) in the external 
module to give the methyl acceptor product (A-CH3)  
MeCbl methionine synthase (MetH)  
From homocysteine methionine is synthesized by shifting of a 
methyl group fromN5-methiltetrahydrofolate. This reaction is 
biocatalyzed by methionine synthase to form MeCbl and Hfolate, this 
shifts the methyl group to Hcy to regenerate cobalamin (I) and to form 
methionine. 
 
Figure shows creation and character of the cofactors and MeCbl, 
AdoCbl heterolytic and homolytic sepration of the Co-C bond in MeCbl 
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Ado Cbl Ado Cbl enzymesare correspondingly demonstrated. The 
consistent arrow specifies the site of changes, heterolysis into the 
cytoplasm and homolysis into the mitochondria. 
5. Absorption& Cellular Uptake of B12 
Higher organism does not have the capacity to synthesize 
cobalamines in the body as they are lacking the necessity enzyme system. 
They have to be supplemented in the food compulsorily. If the 
cobalamines are not taken in the body or if there is defective absorption 
in the enzymatic catalysis may aggravate nervous system disease, in 
adding tovitaminB12 deficiency anaemia. 
In humans the vitamin B12 follows complicated path way for the 
intestinal uptake, different mode of transport, cellular utilisation. The 
carrier proteins, haptocorrin -HC, transcobalamin- TC intrinsic factor 
(IF). They make close-fitting compounds through Cbl. 
The dietary cynocobalamin is exclusively fixed to haptocorrin-HC 
which is a salivary protein and forms HC-Cbl. In the duodenum the 
proteases of pancreatic origin splits into HC and Cabalamine. Then the 
vitamin is fixed with castles factor. Intrinsic –B12 factor compound 
formed. Within the intestinal cells, the intrinsic factor is released. Now 
the vitamin attaches itself tightly with Transcobalamin-Cbl complex. The 
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vitamin undergoes endocytosis in the plasma membrane, and the 
transcobalamin is free for next cycle.  
Within the hepatic tissues TC- undergoes exocytosis, freeing B12. 
By a special process methyl-Cbl (in cytoplasm) 5 -deoxyadenosyl-Cbl( in 
mitochondria) is formed.  
  Currently the researchers have found the truth that the surface 
binding affinity of B12. This property is used in the targeted drug 
delivery in tumour tissues. 
Transport proteins in mammals  
Three carrier proteins are available for the transportation namely 
HC IF and TC. All are peptides. But, HC, IF – undergoes glycosylation. 
All transport protein transports a solitary molecule which forms firm 
attachment with B12 brings a single Cbl molecule which is firmly bound. 
Nevertheless, carrier proteins differs in their specificity in the order HC 
<< TC < IF. Up to 2006, the carrier protein crystallography was not 
conducted though structural study of the enzymes was started in the year 
1994 itself. 
The configuration of human and bovine TC-Cbl compounds are 
identical and contains of twoα and β domains joined together with a 
linker. 
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“The αβ sphere structure of transcobalamin (TC) and human 
intrinsic factor (IF) are similar. The picture displays bi-domain assembly 
of TC. The interior six α coils are in red and the six exterior ones in 
violet84. The β sphere is in blue. The loop linking the spheres is in green. 
b) The bi -domain construction of IF; the inner six α helices are in red and 
the six peripheral ones in violet. The β sphere is in blue.” 
 A
 
B 
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  For long period, the transport and the absorption vitamin B12 in 
human has recommended the usage of Cbl to increase the bioavailability 
of proteins and drugs with reduced solubility and minimal gut 
absorption.83 
Currently vitamin B12 is used in the delivery (proteins peptides) of 
hormones and EPO, more newly, insulin. Furthermore, rapidly 
proliferating cell likes cancer tissues needs greater quantities of Cbl 
comparing to normal tissues, added this property in designing the bio 
conjugates to transfer NMR radio imaging drugs or cytotoxic medicines 
to the tumour tissues.84, functioning conjugates can be engaged as 
“Trojan horses”85 to transport the diagnostic label or anti-tumoural into 
the neoplastic site.  
   Cobalamins are the biochemical name for the B12 vitamer. The 
interesting fact about cobalamins, are -their photosensitivity. They are 
soluble in water. B12 is essential for the growth, maturation of the RBCS 
and also the neurons. . cobalamines are the coenzymes in the 
transformation of homocysteine to methionine. It is again the co factor in 
the synthesis of suuccinyl COA from methyl coA 
B12 Sources  
Humans and higher animals have to synthesis directly or indirectly 
from bacteria. 
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These bacteria are habituated in terminal gut where B12is absorbed 
Animal protein 
Fish and shellfish liver, meat 
Eggs, poultry products milk, 
Chlorella, fresh-water single cell green algae,. to contain biologically 
activeB12 
Fermented black tea which is familiar in Japan called as Batabata-
cha is having the biological potent form of B12  
Risk conditions  
Strict vegetarians, those who are on certain prescriptions, patients 
with assured gastro- intestinal disorders, the persons having poor food 
intake habit, and aged persons in the range of 60-80. 
 Poor nutritional intake defect in the stomach, intestinal and 
terminal ileum can cause deficiency of the B12.  
 With references to the causes, the prevalence of deficiency ranges 
from 5–60%. In general it is 20% only. The vitamin deficiency is not 
specific. It is vague so identifying the symptoms in the early stages is 
very difficult as this is the only water soluble vitamin stored in the liver. 
The deficiency manifestations will take at least 3-4 years to appear. 
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Common Symptoms of B12 Deficiency 
Paraesthesia, weakness, numbness, 
 Neuropathic 
 Ataxia, Abnormal gait 
 Myelopathy  
o cerebral causes ;  
o Depression 
o Memory loss 
o Abnormal gait  
Anaemia (Haematological -not so common)  
Deficiency for a prolonged period ends in the neuronal 
complications like death of the neurons, demyelination, axonal changes 
and apoptosis. So the interventions should be done promptly. 
 RDA FOR VITAMINB12 IN ADULTS 
Age Sex/male 
µgms/l 
femaleµgms/l Pregnancy 
µgms/l 
Lactation 
µgms/l 
19&older 2.4 2.39 2.6 2.4 
50& older 2.4 2.39 - - 
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SCREENING  
There are no official recommendations for the routine screening of 
B12. Guidelines direct the screening in risk persons. Patients are 
according to the risk advised for screening and management. Patients 
with history of malnutrition auto immune disorders genetic defects in the 
absorption are advised to undergo screening reqularly.89 
One suggestion is the people above the age of 50 are advised to 
undergo annual screening every five years up to sixty five years. After 
that annually once up to the age of 80. To determine the status of the 
vitamin in the body , the serum levels itself is taken as a marker recently. 
The highly sensitive marker for the vitamin levels in the body is 
holotranscobalamin, Halo TC. But luckily the commercial use is almost 
not available. . 
The reference range is still a debate. In India it is usually 240 µ/l- 
900µ/l were normal22. This is due to most of them are vegetarians and the 
lower socio economic status. Below 240 pmol23 is considered as 
deficiency status. The serum MMA, homocysteine, folate levels can 
affect the body status of the vitamin. Diseases like coeliac atrophic 
gastritis, liver problems of chronic durations, bone disorders and 
malignancy will also alter the level. MCV used as a marker of the 
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deficiency status is not acceptable as it is not as sensitive, as it misses 
90% of the deficiency status. 
DRUGS 
 Alcohol: Extreme alcohol consumption more than 15 days can 
reduce vitamin B12 absorption.  
 Amino salicylic acid - PAS, para-aminosalicylic augments the 
absorption of oral preparations level up to 55%. During the course 
of treatment Megaloblastes are noticed. Unusual anaemia’s also 
presented in the peripheral blood films. If the dose is more than 
12gms or the duration is more than one month whichever is early 
then the individual must be screened for the vitamin levels. 
 Antibiotics: drugs such as metronidazole will increases the 
B12 level. This response of the drugs over the microbial in the gut 
is controversial yet it has to be proved.  
 Oral contraceptives on B12 serum status are contrasting each other. 
When oral contraception is stopped, the vitamin B12 levels returns 
to usual levels. 
 Cobalt radiation 
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  During any form of radio therapy gut loses the capacity to absorb 
the vitamin. 
 Colchicine:> 3.9 mg/ over 24 hrs causes mucosal atrophy and there 
by a chances of defective absorption. This will take a minimum 
period of 3 years. 
  So screening is advised if colchcine is continued for more than 
three years in mega dose.  
H2-receptorantagoanists        
H2 blockers will interfere with the dietary forms. Supplemental 
forms are not affected by these drugs. Gastric juice is needed to free, 
dietary salivary protein bound forms. As acid levels are reduced by these 
drugs monitoring of the B12 levels are suggested if the therapy is 
continued for unusual durations. 
Metformin-Glucophage – definitely reduces the capacity of the 
cubilin receptors which is dependent on calcium uptake. Sustained use 
will leads to B12deficiency and. hyperhomocysteinemia, by interfering 
with folic acid metabolism through the co enzyme the raised 
homocysteine which is "individual risk90 for cardiovascular disease, 
particularly amongst those with type 2 diabetes." 
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  Infrequent form of megaloblasts has demonstrated in the 
individuals those who are taking the biguanides for 6 years are 
more. The incidence of drug induced vitamin deficiency is about 
22-30% in these persons. 
  If the nutritional status of the individual is satisfactory the 
deficiency is doubtful. The supplementation of calcium also revert 
the drug induced deficiency status. If adequate formulations are 
taken then the deficiency is not occurs even in chronic course of 
the doses. 
 Neomycin: though it interferes with the cellular uptake of the 
vitamin at the intestinal levels. Pernicious anaemia occurs if mega 
therapy is continued for longer periods. Supplementation is not 
needed in the regular doses. 
 Nicotine: -decreases B12 levels. The requirement of oral formulas is 
yet to be proved.  
 Nitrous oxide: because of oxidation the Cobolamine are become 
incapable for enzymatic reactions myelopathy, sensory neuropathy, 
encephalopathy occurs according to the vitamin status of the 
individual. The response to treatment therapy is very slow though 
high doses are supplemented.91 
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Phenytoin, Phenobarbital, Primidone: These anticonvulsants are 
related with defective absorption of B12. In CSF and the serum the levels 
are decreased. So the megaloblastic anaemia takes the upper hand. 
 Certain drugs can also disturb B12levels. 
The sustained use of metformin for diabetes can drop B12levels 
adequately to gain the clinical significance. Sometimes the neuropathy of 
T2DM can be considered as neuropathies of the vitamin deficiency. Both 
are separate issues. 
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MATERIALS AND METHODS 
 
 
  This research was conducted during the period April 2015– August 
2015 as a cross sectional comparative type in the department of 
Diabetology, department of Biochemistry in Kilpauk Medical College 
Chennai. 
 STUDY POPULATION:  
• CASES: 
45 patients of known type II diabetes mellitus on metformin for a 
period of 12 months will be selected as cases from OPD of Department of 
Diabetology, Govt. Kilpauk Medical College & Hospital (GKMCH), and 
Chennai. 
CONTROLS 
• Control group consists of 45 known persons with T2DM not on 
biguanides like metformin in the past one year. Controls are age 
and sex matched.  
• INCLUSION CRIETERIA  
• 40 to 60 years of Previously diagnosed T 2 DM 
• Both genders (female & male) are included.  
• Those who are on insulin & other OHA drugs also included.  
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• EXCLUSION CRITERIA 
•  History of anaemia, 
• Prior transfusion,  
• Renal insufficiency,  
• Thyroid illness,  
• Alcohol intake,  
• Prior gastric surgery, proton pump inhibitors, those with 
malabsorption syndrome  
The study was approved by the Institutional Ethical Committee of 
GKMC, Chennai. After a full explanation of the study a written informed 
consent was obtained from each participant. 
SAMPLE COLLECTION: 
  
• 3 ml random venous blood sample was drawn from ante cubital 
vein of patients, after fulfilling selection criteria in a plain test tube. 
Sample is separated by centrifugation at 3000 rpm for 15 minutes; 
within 2hrs of collection separated serum is stored at -20 c for further 
analysis. 
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Estimation of Plasma Glucose: 
  
Method: Glucose Oxidase peroxidase (GOD / POD )( End point Test ) 
 
Kit used: Erba 
 
Principle: 
              Glucose Oxidase  
Glucose + O2+H2O      Gluconic acid + H2 O  
 Peroxidase  
 
                            Pink coloured complex 
H2O2+4APP+PHENOL    QUINONEIMINE COMPLEX+ H2O   
 
a.  Pink coloured Quinonemine complex is developed to depending 
on the glucose concentration in the sample. Absorbance was read at 
505 nm. 
Composition of reagents 
Reagent -1: Enzyme reagent  
Peroxidase ->2000U/L 
Glucose oxidase - 20000U/L  
Phosphate buffer - 200 mmol/ 
L Phenol - 10 mmol/L 
Glucose standard - 100 mg/dl  
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Procedure:  
10µl of plasma was added to 1000µl of working reagent and 
incubated for at 37.c 15 minutes.  
Reference range:  
 
 Fasting plasma glucose -70- 110mg/dl 
  
Blood Urea Estimation  
 
Kit used: Accucare  
Method: Urease - GLDH (kinetic UV test) 
Principle:  
Urea is hydrolysed to Urease in the presence of water which 
produces ammonia and carbon dioxide. In the presence of glutamate 
dehydrogenase the ammonia joins with NADH and oxoglutarate to give 
glutamate and NAD.  
            Urease 
 Urea + H2 O    2NH4+ H2O 
 
                 GLDH 
 NH4+ NADH + H+ 2-oxoglutarate    Glutamate + NAD 
 
The rate of reduction in absorbance is initially directly related to 
the amount of urea in the solution. The readings are taken at 340 nm.  
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Composition of Reagent  
Reagents I: Buffer reagent  
Reagent II: Enzyme reagent  
Urea standard: 50 mg/dl  
Preparation of reagent 
1ml of Enzyme is taken along with4 ml of Buffer reagent both are 
mixed gently. 
Methods 
10µl of plasma is added to 1000µl of reconstituted reagent and 
absorbance measured at 340 nm. After 30 secs and 60 secs the rate of 
reduction is directly related to amount of Urea in the solution.  
Reference range: Serum / Plasma Urea → 15 – 39 mg/dl.  
 
 Creatinine Estimation: 
Kit used: Erba 
 
Method: Jaffe’s method (Picrate Method) (Initial rate method) 
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Principle  
 
Creatinine when mixed with alkaline picrate after a chemical 
reaction it produces an orangish – yellow colour which is called - Jaffes 
reaction Colour of the absorbance is directly related to the amount of 
creatinine in the given solution. Absorbance is measured at 500nm.  
composition 
Reagent 1: picric acid reagent 
Picric acid - 25.8 mmol 
 
 
Reagent 2:  
 
Sodium hydroxide – 95 mmol/L 
  
Sodium hydroxide reagent 
 
Standard  
  
2mg/dl (0.166 mmol/L)  
 
 
Preparation of reagent 
  
Both the reagents are mixed with equal volumes. After 15 minutes, 
it is used. 
Procedure: 
  
100µl of the sample is added to 1000µl of the reconstituted reagent 
and mixed gently and immediately the reading is taken. Difference in the 
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initial absorbance after 20 secs and final absorbance after 80 secs of 
correct mixing, the readings are taken. 
Reference range: 
  
Male: 0.6 – 1.1 mg/dl,  
Female: 0.5 – 0.9 mg/dl. 
 
Human Vitamin B12- ELISA 
 
Uses of the kit 
  
  
The kit is based on sandwich technique of ELISA for the 
measurement of HumanVB12 in biological fluids 
COMPONENTS  
  
Reagents Quantity  
Pre-coated, ready to use  
96-well plate  1 
 
Calibrator Diluent   1 × 20 mL 
Calibrator (lyophilized)   2  
Detection Reagent A   1 × 120 µL 
Detection Reagent B   1 × 120 µL 
Assay Diluent A   ( 2x concentrate) 1 x6mL 
Assay Diluent B   (2X concentrate) 1 × 6 mL 
Stop Solution   1 × 6 mL 
TMB Substrate   1 × 9 mL 
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Wash Buffer  
(30X concentrate)   1 × 20 mL 
 
Plate cover for all the wells   
REQUIRED MATERIALS 
 
 Eppendorf Tubes for diluting samples. 
 Deionized or distilled water 
 Precision single and multi-channel pipettes and disposable tips. 
 Container for Wash Solution 
  Absorbent paper for blotting the microtiter plate 
 Micro plate reader with 450 ± 10 nm filter. 
 STORAGE 
 
  
PRINCIPLE 
According to their label all reagents are stored. The Calibrators 
Detection Reagent B Detection Reagent A and the 96-well plate are 
stored in the deep freezer at -20°C. The additional strips are kept in a 
protected bag to avoid the atmospheric air. Opened kits are stable, till the 
expired period if kept correctly. 
The microtiter wells are pre- treated with VB12 specific antibody 
samples and to the exact microtiter, the exact calibrators a with a specific 
VitB12 biotin-conjugate are added. 
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  Horseradish Peroxidase (HRP) avidin is then added to each micro 
well after the correct incubation period. Then substrate of TMB is added. 
Now the vitaminB12 conjugate undergoes reaction with avidin conjugate 
which will show a colour change. The substrate enzyme reaction is 
resolved by addition of sulphuric acid. The colour changes are read 
spectrophotometric ally at a 450 nm ± 2 nm wavelength. The VitaminB12 
levels in the test solution are determined by comparing the O.D. of the 
calibration curve to the test solution curve. 
STORAGE OF COLLECTED SAMPLE 
Serum  
The samples which were collected in the plain test kept for 2 hours 
in the room temperature for clot formation. Then centrifugation done 
at1000 x g for 20 minutes .Serum separated freshly is used immediately 
or transferred in aliquots and kept in deep freezer in -20°C or -80°C to 
future use. Repeated freezing are avoided 
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Note:  
1.  The samples stored in2-8°C,are used within 5 days, otherwise they 
are kept at deep freezer 20°C -80°Cto elude contamination and to 
maintain the potency. 
 
2.  Samples are brought to room temperature then assay is done.  
3. As haemolysis will impact the result. (Haemolysis must be 
avoided)  
PREPARATION OF REAGENT 
Samples and all components in the kit are allowed as such for (18-
25°C) 20 minutes. 
Calibrators  
The Calibrator are mixed with respectable diluents as per the guide 
lines and allowed for the incubation time of ten minutes. By mixing 
slowly and gently foaming can be avoided. The stock calibrator is now at 
the concentration 1000 pmol/L. With the help of Diluent and the stock 
solution of the calibrator’s different range of the calibrators are prepared. 
From the stock Calibrator 500µl is added to six tubes and different 
concentration of sub stock of prepared (as given below fresh tip is used 
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for each delivery and every tube is mixed completely before subsequent 
delivery. calibrators will have seven concentrations of 1,000, 500, 250, 
125, 62.5, 31.2, 15.6, pmol/L, final tube contains only the Diluent will be 
the blank at 0 pmol/L.. 
  
 
    1  2   3    4    5    6   7    8 
 
Tubes 
 
-pmol/l1000 500 250 125 62.5 31.5 15.6 0 
Assay Diluent A and B Six mL of deionized water six ml of Assay 
Diluent A is added so twelve mL of working solution is made. Then with 
same procedure with help of Assay Diluent WORKING SOLUTION OF 
B is prepared. Both are kept correctly as per the guide lines. 
Detection Reagent B AND A 
Both detection reagents A &B are spinned. By diluting the working 
Assay Diluent A or B, sub concentrations are prepared individually 
(1:100). 
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SOLUTION FOR WASH 
By adding twenty ml of wash solution to five eighty ml of distilled 
water the solution for wash is prepared. 
TMB Substrate  
Only the required substrate is pipetted with fresh tips and the 
remaining solution are discarded, not returned to bottle meant for 
substrate 
Notification 
Reagents are not dissolved at37°C. 1 
1.  The calibrators are. Prepared within 15 minutes before the assay 
commencement 
2.  The dilutions are added not directly to the micro plate. 
3.  Calibrators and the working Reagent A, B are added as per the 
instruction. As per the recommendations the reconstitution is done. 
Care is taken to see whether the crystals are dissolved fully or not. 
Foaming is avoided during the procedure. To reduce pipetting 
inaccuracy small volumes are used. Pipettes with calibration are used 
for the same purpose. Every time only ten µl is pipetted.  
4.  Diluted Calibrators, all the Reagents are for single time use.  
 60
5.  The Wash Solution (30X) must be free of crystals. If not the solution 
is slowly mixed till it is dissolved fully. 
PROCEDURE 
  Before starting the assay the concentration of vitamin b12 is 
estimated. If the values are not seen in the detection limit of calibration 
curve, dilutions are done. Correct wells are kept for proper diluted 
calibrators, blank and test. For calibrators, seven micro wells are prepared 
One well for blank is kept separately. Blanks and calibrators are 
added in to the concerned micro wells then the test is added to the 
remaining microtiter plates. Hundred µL of e Detection Reagent A 
solution is added to every micro plate after covering with silver paper 
incubated at 37°C for 2 hours. 
2.  From each well, the liquid removed not washed. 
3.  The solution is aspirated first then and each well is washed with 
four hundred µL of Solution for wash ,with a wash bottle, wash can 
done manually or automated washer with for one –two minutes till 
all the micro plates are dried fully. Invert all wells on a filter paper. 
3 times this is repeated for. After the last wash any drop of liquid 
missed is removed by Wash Buffer aspirating or decanting. 
4.  The plates are inverted against a filter paper.  
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5.  To working solution, 100 µL of Detection Reagent B is added to 
each well. After covering with the silver paper incubated for thirty 
minutes at 37°C 
6.  The wash procedure and aspiration is done repetitively for five 
times like the previous procedure.  
7.  Substrate ninety µl is added to every well after covered proper 
coverings at 37°C incubation done for 15 - 25 minutes (The 
solution will turn blue after the addition of Substrate Solution. 
Protect the wells from light. 
8.  To each well 50 µL of Stop Solution is added. Now the liquid will 
turn yellow. The side of the plate is tapped slowly so the liquid is 
mixed gently. If the colour change is not uniform, the plate is 
gently tapped to verify full mixing.  
9.  Fingerprints drops of solution or on the bottom of the plate are 
removed and confirmed, the surface of the liquid is seen without 
any bubbles. Then the plates are kept in the micro plate reader and 
measurements are taken at450 nm reading is taken at once. 
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RESULTS  
The duplicate readings for each calibrator, control, and sample are 
averaged and subtracted from the average zero calibrator optical density.  
A calibration curve a calibration curve is produced by manoeuvring of 
mean absorbance y-axis against the concentration. A straight line made 
between the points. The statistics may be corrected by plotting the log of 
the VB12 concentrations versus the log of the O.D 
PERFORMANCE 
Detection Range  
The detection range is: 15.6 – 1,000 pmol/L. 
The calibration curve concentrations used for the ELISA’s were 
1,000, 500, 250, 125, 62.5, 31.2, 15.6 pmol/L. 
Sensitivity  
The lowest measurable value of Human VB12 is classically less 
than 3.9 pmol/L. Lower Limit of Detection (LLD) or the sensitivity of 
this assay, is demarcated as the lowest amount of concentration that could 
be renowned from zero. It was determined by the mean O.D. value of 20 
duplicates of the zero calibrator plus three standard deviations.  
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RESULTS AND STATISCTICS 
1. Age wise distribution of participants among study groups 
 
 
Group N Mean
Std. 
Deviation 
Std. Error 
Mean 
P 
value 
Age in 
years 
Control 45 43.31 10.377 1.547 
  
Cases 
45 49.96 12.019 1.792 
.006
 
Age based distribution into Test and Control groups were also 
statistically significant. Insulin was used predominantly among patients 
between 30 to 60 years in our study, but metformin use among test group 
participants was widely dispersed. 
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2. Duration of Diabetes among study participants 
Group N Mean Std. Deviation 
Std. Error 
Mean 
P 
value 
Duration of 
DM 
Control 45 5.1333 4.27253 .63691 .632
  
Cases 
45 5.5111 3.08679 .46015 
 
No statistical significance was obtained with regards to duration of 
diabetes pharmacotherapy between control and test group 
3. Independent t-test between control and test with regards to glucose 
levels 
  Group N Mean Std. Deviation P value
Glucose Control 45 138.242 25.9523 
0.575  
Cases 
45 142.331 41.2443 
 
  In our study conducted among 45 Test (Receiving Metformin) and 
45 control (Receiving Insulin other anti-diabetic medication), no 
statistically significant inter-group variation existed with regards to 
glycaemic levels during recruitment. 
4. Variation in RFT between control and test (independent t test) 
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 Urea   
  Group N Mean
Std. 
Deviation 
Std. Error 
Mean 
P 
value 
Urea Control 45 27.160 6.3434 .9456 
 Cases 45 28.178 8.7029 1.2974 .528
 
Creatinine 
  Group N Mean
Std. 
Deviation 
Std. Error 
Mean 
P 
value 
Creatinine Control 45 1.0211 .26128 .03895 
 Cases 45 .8663 .40739 .06073 .035
 
Between the test and control group, significant intergroup 
variation was seen in creatinine value, but not in urea levels when 
independent student’s t test was applied separately for each parameter. 
5. Difference in B12 levels between cases and controls  
 
 
 
 66
 In this among the controls 3 had the low vitamin level and 9 had 
normal level 33 had high level which comes in the following % 
respectively7.6,21.4 &69.8where as in cases it is16.5 42.6, 34.6so 
metformin group had noticeable vitaminB12deficiency prevalence 
comparing their control. 
 Group N Mean 
Std. 
Deviation 
Std. Error 
Mean 
P value
B12 Control 45 1111.202 414.7199 61.8228 <.001**
 Cases 45 754.504 395.7267 58.9915 
 
When study participants were analyzed for intergroup differences 
in B12 levels, the mean difference in B12 levels between Control (Insulin 
+ non biguanide OHA) and Test (Metformin) group was 356.70mcg/dl, 
and when independent t test was applied, highly statistical significant 
values with p values <.001 was obtained. 
6. Correlation of variables in control arm. 
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In Pearson Correlation analysis, significant linkage was seen 
between duration of Diabetes and B12 levels among the 45 patients 
taking Insulin therapy (with/without other OHA), the other variables were 
not significantly correlated.  
7. Correlation of variables in Case arm. 
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Among cases (patients taking Metformin), statistically high significant 
correlation (p value <.001) was obtained between: 
 Metformin use and B12 levels (i.e., B12 level decreases as 
metformin use increases –Negative correlation) 
 Similar to control group, duration of diabetes and B12 levels were 
also positively and significantly correlated. 
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 DISSCUSSION  
  In this cross sectional study, 90type 2DM patients were enrolled 
and they were divided in two groups those who are taking metformin 
considered as cases where as patients on insulin and other oral 
hypoglycaemic agents are taken as controls.  
 The cases on metformin had the prevalence of vitaminB12 
deficiency is 16.6% which is significance on regards to controls. It is also 
dependant on the dose and the duration of drug and the duration of 
disease. But in the control group the deficiency prevalence is7.6% but in 
Rah eels Pakistan study conducted in 2013 had a prevalence of 
31%which had same results with Marar o and friends of Irish study. The 
sample size in both populations was large comparing with this study 
population. Rah eel and his colleague done this study over a period of one 
year they also studied the methyl malaonic acid level for the sensitivity of 
vitamin B12. 
 Our study has limitation since we have not assed the homocysteine 
level, methyl melanoic acid and the folate levels which will also alter the 
vitamin status. 
 Age based distribution in the Test and Control groups were also 
statistically significant. Insulin was used predominantly among patients 
between 30 to 60 years in our study, the mean age of the control group is 
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45 which are 10 years less than Irish and Pakistan study but metformin 
use among test group participants was widely dispersed.  
Between the test and control group, significant intergroup variation 
was seen in creatinine value. Which are not included in the previous 
studies. It shows if the glomerular filtration is good, there is a minimal 
risk of developing B12 deficiency. 
In this among the controls 3 had the low vitamin level and 9 had 
normal level 33 had high level which comes in the following % 
respectively7.6,21.4 and 69.8where as in cases it is16.5 42.6, 34.6so 
metformin group had noticeable vitaminB12 deficiency prevalence 
comparing their control 
 Irish defined levels of less than 100 pg/ml as vitamin B12 
deficiency but as per the Indian guide lines we included 240-900µmol/l5 
among cases (patients taking Metformin), statistically high significant 
correlation (p value <.001) was obtained between: 
 Metformin use and B12 levels (i.e., B12 level decreases as 
metformin use increases –Negative correlation) 
 Similar to control group, duration of diabetes and B12 levels were 
also positively and significantly correlated. Ting et al had done a study in 
the year 2010and observed the same report. Pflipson et al had the same 
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result of 22% prevalence, they did the study only through old medical 
reports. 
 Ting et al, noticed dose of metformin duration are main factors for 
Vitamin B12 deficiency .This is similar to our study showing noteworthy 
association and opposite relation dose, duration of metformin with B12 
levels. 
 Marar O had done the homocysteine and serum methyl malonic 
acid status and urinary excretion of methyl malonic acid amount also, 
which are the highly sensitive markers of vitamin B12,they have assessed 
the neuropathic status also. But they didn’t get the consistent findings 
CONCLUSION 
 
 This cross-sectional comparative study concludes that the persons 
with type 2 DM on chronic metformin therapy showed lower levels of 
serum vitamin B12 status compared to persons not treated with 
metformin. This represented that metformin takes a possible risk for 
vitamin B12 deficiency. The study highlights the need of testing B12 
level, when patients are prescribed metformin for long period thereby 
preventing from its impending side effects.  
 The study recommends base line B12 levels in high risk patients 
before starting metformin therapy. It also recommend vitamins screening 
if therapy is advised for prolonged periods to avoid the neuropathic 
 71
complication which are more common in type 2diabetics due to the 
advanced glycation end products. Doctors treating type 2DM should 
consider this significant point when treating diabetic patients with 
metformin, and particularly with those who present with neuropathic 
signs and symptoms. 
FUTURE SCOPE 
 Holo transcobalamin is a most specific indicator of cobalamin level 
for determining B12 vitamin present within the cells, but this is not 
possible in routine screening. MMA, homocysteine reflects intracellular 
B12 deficiency, but these compounds may also be elevated in numerous 
conditions, particularly in reduced renal function. Exclusion criteria were 
well-defined in this study with regards to increased methyl melanoic acid 
levels. More studies are needed to support our findings in future. 
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PROFORMA 
 
 
Name  :  Age: M/F    
OP/IP no  :  Address :    
Occupation :  
Presenting Complaints:  
Past H/O:  
DM-duration / HT/ Hypercholestrolemia/ Hypothyroid/ IHD/ Endocrine 
Disorder/ Renal Disease/Hepatic Disease. 
Treatment H/O: [on insulin, GLP1 analogs,other OHAS, proton pump 
inhibitors / vitamin supplementation / calcium supplementation/ blood 
transfusion]  
DRUGS OHAS- single/ combination /duration / 
Personal H/O: smoking /alcohol/tobacco chewing  
Family H/o:  
O/E:  
Built - obese/thin/moderate BMI:  
Height- Weight- Waist-  
Pedal edema /Anemia / Lymphadenopathy-  
Vitals:  
 BP: Pulse Rate:  
 Systemic examination:  
 CVS:  RS:   
 CNS:  Abdomen:   
Diagnosis:  
Investigations:  
Blood sugar –  
Sr.Urea :  
Sr. Creatinine:  
Sr. Vitamin B12 
 



